Abstract: We analyzed the baseline and 3-year T1-weighted magnetic resonance imaging data of 110 amnestic mild cognitive impairment (MCI) participants with minimal hippocampal atrophy at baseline from the Alzheimer's Disease Cooperative Study group MCI Donepezil/Vitamin E trial. Forty-six subjects converted to Alzheimer disease (AD) (MCIc), whereas 64 remained stable (MCInc). We used the radial distance technique to examine the differences in lateral ventricle shape and size between MCIc and MCInc and the associations between ventricular enlargement and cognitive decline. MCIc group had significantly larger frontal and right body/occipital horns relative to MCInc at baseline and significantly larger bilateral frontal, body/occipital, and left temporal horns at follow-up. V entriculomegaly is commonly observed in most neurodegenerative disorders and results from passive enlargement of the lateral, third and fourth ventricles as a result of brain parenchymal shrinkage. Ventricular expansion has received considerable attention in the Alzheimer disease (AD) literature. 1-3 Several studies have shown that AD subjects demonstrate both larger ventricles and faster rates of ventricular expansion over time, compared with groups of normal elderly and mild cognitive impairment (MCI) subjects. 1,4-8 In healthy elderly subjects, ventricular volume 1,2 and its rate of change 3 are both associated with future cognitive decline to MCI and dementia. Ventricular enlargement correlates with cognitive decline 4, 7, 9 and has been also shown to associate with cerebrospinal fluid levels of amyloid b and apolipoprotein E4 (ApoE4) genotype. 2, 3 The 3-year-long Alzheimer's Disease Cooperative Study (ADCS) studied the efficacy of donepezil and vitamin E for delaying the progression of MCI to AD in a doubleblind randomized placebo-controlled manner. 10 Neither agent influenced progression to AD. Yet the imaging data of the ADCS Donepezil/Vitamin E MCI trial has resulted in several important observations to date. 11-14 Donepezil showed a trend-level significant effect on hippocampal atrophy rates. 14 Subjects with moderate to severe hippocampal involvement-visually graded by experts using the medial temporal atrophy (MTA) rating scale-had double the risk for future conversion of MCI to AD. 12 Recently, a publication from our group documented the gradual progression of hippocampal atrophy from the subiculum and CA1 to the CA2-3 in the subset of MCI patients with none to mild hippocampal atrophy at baseline as classified by DeCarli et al, 12 providing for the first time a true in vivo dynamic map of the spread of hippocampal neurodegeneration in early AD. 11 Manual ventricular delineation is time consuming and tedious and is unsuitable for studies with large sample sizes. Recent ventricular automated segmentation approaches have finally allowed us to better understand and track structural changes in the lateral ventricles as a diagnostic and prognostic AD biomarker. [3] [4] [5] [6] 15, 16 Our group recently showed that although AD and MCI have significantly
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entriculomegaly is commonly observed in most neurodegenerative disorders and results from passive enlargement of the lateral, third and fourth ventricles as a result of brain parenchymal shrinkage. Ventricular expansion has received considerable attention in the Alzheimer disease (AD) literature. [1] [2] [3] Several studies have shown that AD subjects demonstrate both larger ventricles and faster rates of ventricular expansion over time, compared with groups of normal elderly and mild cognitive impairment (MCI) subjects. 1, [4] [5] [6] [7] [8] In healthy elderly subjects, ventricular volume 1,2 and its rate of change 3 are both associated with future cognitive decline to MCI and dementia. Ventricular enlargement correlates with cognitive decline 4, 7, 9 and has been also shown to associate with cerebrospinal fluid levels of amyloid b and apolipoprotein E4 (ApoE4) genotype. 2, 3 The 3-year-long Alzheimer's Disease Cooperative Study (ADCS) studied the efficacy of donepezil and vitamin E for delaying the progression of MCI to AD in a doubleblind randomized placebo-controlled manner. 10 Neither agent influenced progression to AD. Yet the imaging data of the ADCS Donepezil/Vitamin E MCI trial has resulted in several important observations to date. 11-14 Donepezil showed a trend-level significant effect on hippocampal atrophy rates. 14 Subjects with moderate to severe hippocampal involvement-visually graded by experts using the medial temporal atrophy (MTA) rating scale-had double the risk for future conversion of MCI to AD. 12 Recently, a publication from our group documented the gradual progression of hippocampal atrophy from the subiculum and CA1 to the CA2-3 in the subset of MCI patients with none to mild hippocampal atrophy at baseline as classified by DeCarli et al, 12 providing for the first time a true in vivo dynamic map of the spread of hippocampal neurodegeneration in early AD. 11 Manual ventricular delineation is time consuming and tedious and is unsuitable for studies with large sample sizes. Recent ventricular automated segmentation approaches have finally allowed us to better understand and track structural changes in the lateral ventricles as a diagnostic and prognostic AD biomarker. [3] [4] [5] [6] 15, 16 Our group recently showed that although AD and MCI have significantly larger lateral ventricles relative to cognitively normal elderly, there was very little difference between MCI and AD subjects, suggesting that the lateral ventricles are a viable early AD disease biomarker. 17 One group applied another automated ventricular extraction technique to a small sample of MCI subjects from the Alzheimer's Disease Neuroimaging Initiative and reported that MCI subjects who later converted to AD (MCIc) showed significantly greater rates of ventricular enlargement relative to those who remained stable (MCInc) over 6 months. 6 In this study, we analyzed the baseline and 3-year T1-weighted magnetic resonance imaging (MRI) data of the 110 ADCS Donepezil/Vitamin E MCI trial participants who had both a baseline and month 36 scans and minimal hippocampal atrophy at baseline defined as MTA score <2. Our goals were to apply advanced computational anatomy methods to examine and quantify the longitudinal ventricular changes in MCIc and MCInc and to examine the associations of progressive ventricular enlargement with cognitive and functional decline. We hypothesized that MCIc would show larger ventricles at baseline and in follow-up and faster ventricular expansion rates than MCInc. We also hypothesized that cognitive and functional decline will associate with progressive ventricular enlargement over time.
SUBJECTS
The 69 North American sites of the ADCS MCI Donepezil/Vitamin E trial enrolled a total of 769 amnestic MCI subjects all of whom had insidious, gradually progressive memory decline, a Logical Memory delayed recall score at least 1.5 standard deviations below an educationadjusted norm, a Clinical Dementia Rating score of 0.5 and a Mini-Mental State Examination (MMSE) score between 24 and 30. The demographic characteristics of the full sample are described elsewhere. 10 The primary outcome of the study was defined as conversion to possible or probable AD according to the National Institute of Neurologic and Communicative Disorders and Stroke and the AD and Related Disorders Association criteria. 18 Twenty-four of the 69 sites opted to participate in the MRI arm of the study. Clinical trial subjects at these 24 sites were approached for participation in the MRI substudy; those who were willing to participate and had no contraindications to MRI were included. The final MRI sample consisted of 194 participants who received a baseline and a 3-year MRI scan, in addition to all standard clinical trial procedures. The MCIc group received an additional scan at the time of conversion to AD.
Of these 194 subjects, 110 subjects with minimal or no MTA based on visual assessment with the MTA rating scale as previously described by DeCarli et al 12 had baseline and follow-up scans of sufficient quality for our analyses. Minimal hippocampal atrophy, that is, a rating of 1 on the MTA rating scale, is assigned when the structural changes in the medial temporal lobe structures are no more severe than those expected from aging alone. 19 Forty-six out of our 110 MCI subjects converted to possible or probable AD (MCIc) over the 3-year follow-up interval, whereas the remaining 64 did not (MCInc).
MRI Acquisition, Preprocessing, and Analyses
All MRI data were acquired at 1.5 T. Of the 24 sites, 14 used General Electric scanners, 9 Siemens, and 1 Philips scanner. We analyzed the three-dimensional (3D) coronal spoiled gradient echo (SPGR) or equivalent T1-weighted scan with minimum full-time echo, minimum repetition time, 124 partitions, 25-degree flip angle, and 1.6-mm slice thickness. Each subject's T2-weighted scan was inspected for strokes or significant white matter hyperintensities at the main image repository site (Mayo Clinic, Rochester, MN). Only scans devoid of such abnormalities were shared with the University of California Los Angeles (UCLA) research team. All data were checked for quality and compliance with the imaging protocol as described elsewhere. 14 The ADCS and the UCLA Institutional Review Board approved the analyses reported here. Baseline and followup images were each registered separately to the ICBM53 standardized brain template using a 9-parameter linear transformation 20 and subjected to intensity normalization. 21 We used our recently developed semiautomated ventricular segmentation approach, called multi-atlas fluid image alignment, which has been previously described. 5 Briefly, an experienced human rater (A.E.G., intrarater reliability Cronbach a = 0.995) hand-traced the lateral ventricles of 4 subjects. These traces were converted into 3D parametric ventricular mesh models and were used as primers for segmenting the remainder of the data set by fluid propagation over the ventricles of the rest of the subjects in the study. Using fluid registration, each primer was separately warped to match and thereby extract the shape of the lateral ventricle of each new subject's scan resulting in four lateral ventricle segmentations per subject. These four segmentations were then averaged (using 3D vector averaging of mesh surface points) to create one final ventricular model for each subject that most accurately captured individual anatomy. This substantially reduces segmentation errors that occur when only 1 atlas is used. The ventricular models were split up into frontal, inferior, and body/occipital partitions. The medial core (a medial curve threading down the center of each partition) and the radial distance from the medial core to each ventricular surface point were computed.
Statistical Analyses
We used the two-tailed Student t test to compare the mean age, education, and MMSE scores between MCIc versus MCInc at baseline. The w 2 test was used to compare sex, ApoE4 genotype and treatment arm distribution between the 2 groups.
We used multiple linear regression with ventricular radial distance as the outcome measure and diagnosis as the predictor variable for between-group comparisons at baseline and at follow-up. We also directly compared the rate of ventricular enlargement in MCIc versus MCInc. Our longitudinal within-group assessments used the study time point (baseline vs. follow-up) as the predictor variable. The former reveals differences between groups at each time point and the latter assesses progressive ventricular enlargement in each group over time.
Next, we used linear regression with % change in ventricular radial distance between scanning time points as the dependent variable and the following global cognitive and functional measures as predictor variables-change in MMSE, change in Activities of Daily Living (ADL) score, and change in AD Assessment scale cognitive subscale (ADAScog) score. After examining the pattern of associations, we repeated these analyses while controlling for hippocampal atrophy over time (measured as % change in hippocampal volume), baseline frontal horn volume, and total ventricular volume. Next, we also investigated the associations between verbal memory decline (ie, change on ADAScog delayed word recall), visuospatial decline (ie, change on ADAScog constructional praxis score), and executive decline (ie, change in Maze task total errors score) and ventricular enlargement. Our 3D statistical maps were further corrected for multiple comparisons using permutation tests at a predefined threshold of P < 0.01. Permutation analyses derive a single overall corrected P-value for each 3D statistical map based on the number of surface points surviving a particular a priori threshold (for more details on the permutation approach, please refer to Thompson and Apostolova 22 ). All analyses were repeated with ventricular volumes.
RESULTS
MCIc and MCInc groups were well balanced with respect to age, sex, education, and treatment arm. The MCIc group had a significantly higher proportion of ApoE4 carriers, significantly worse MMSE, total ADAScog, ADAS verbal memory, Maze errors and ADL scores, and hippocampal and right frontal horn volume at baseline, as well as significantly greater decline in MMSE, total ADAScog, ADAS verbal memory, ADAS construction, and ADL score over time relative to the MCInc group (Table 1) .
MCIc Versus MCInc Comparisons at Baseline and Follow-up
At baseline, the MCIc group had significantly larger frontal (left P corrected = 0.012, right P corrected = 0.008) and trend-level larger right body/occipital horns (P corrected = 0.055) relative to MCInc. Quantitatively, areas with significant between-group differences showed up to 15% larger ventricular radial distance in MCIc relative to MCInc (Fig. 1, left panel) . The volumetric between-group differences at baseline were restricted to right frontal horn only (P = 0.006).
At 3-year follow-up, the frontal horn differences between MCIc and MCInc were even more pronounced (left P corrected = 0.0024, right P corrected = 0.0015, Fig. 1 , right panel), whereas posterior ventricular differences were now observed bilaterally (left body/occipital horn P corrected = 0.022, right body/occipital horn P corrected = 0.006). MCIc also showed significant right and trend-level left temporal horn enlargement relative to MCInc at follow-up (left P corrected = 0.06, right P corrected = 0.043). The volumetric between-group comparisons at 3-year follow-up revealed larger right frontal (P < 0.0001) and left occipital horn (P = 0.005).
Within-group Longitudinal Analyses
Over the 3-year duration of the trial, the MCIc group experienced progressive enlargement of the body/occipital horns of the lateral ventricles (left P corrected = 0.032, right P corrected = 0.048; Fig. 2, left panel) , whereas the MCInc group failed to show significant ventricular enlargement over the 3-year period (Fig. 2, right panel) . Figure 3 shows the average 3-year % change in ventricular radial distance in MCIc and MCInc (top left and right, respectively) as well as the direct statistical comparison of the magnitude of ventricular enlargement in MCIc and MCInc over the course of the study (bottom). MCIc subjects showed significantly greater ventricular enlargement of the body/occipital horns bilaterally (left P corrected = 0.02, right P corrected = 0.0055) and the right frontal horn (P corrected = 0.031) relative to MCInc. The volumetric comparisons failed to reveal any differences in % enlargement between the two groups.
Associations Between Cognitive and Functional Decline and Ventricular Enlargement
Changes in ADAScog and MMSE scores over the trial duration in the pooled sample showed significant or trendlevel association with progressive ventricular enlargement of the temporal horns (ADAScog left P corrected = 0.038, right P corrected = 0.056; MMSE left P corrected = 0.2, right P corrected = 0.026) and body/occipital horns (ADAScog left P corrected = 0.028, right P corrected = 0.0022; MMSE left P corrected = 0.024, right P corrected = 0.015; Fig. 4 ; Table 2 ). After controlling for baseline frontal horn volume, total Decline on ADAScog delayed word recall showed significant association with enlargement of the left temporal (P corrected = 0.026) and right body/occipital horn (P corrected = 0.0015) in addition to a trend-level association with the left body/occipital horn (P corrected = 0.073; Fig. 4 ; Table 2 ). After controlling for baseline frontal horn volume, total ventricular volume, and hippocampal atrophy, the pattern of associations remained largely unchanged ( Table 2 , maps not shown).
ADAScog constructional praxis decline showed significant bilateral associations with enlargement of the body/ occipital horn (left P corrected = 0.0051, right P corrected = 0.019) and the right frontal horn (P corrected = 0.049; Fig. 4 ; Table 2 ). After controlling for baseline frontal horn volume, total ventricular volume, and hippocampal atrophy, the pattern of these associations remained unchanged ( Table 2 , maps not shown).
Executive decline assessed with the Maze error score was associated with progressive enlargement of the right frontal (P corrected = 0.047) and left temporal horns (P corrected = 0.036; Fig. 4 ; Table 2 ). After controlling for baseline frontal horn volume, total ventricular volume, and hippocampal atrophy, the pattern of these associations remained unchanged (Table 2 , maps not shown).
ADL decline was significantly associated with enlargement of the body/occipital horns bilaterally (left P corrected = 0.004, right P corrected = 0.032) and the left temporal horn (P corrected = 0.019) as well as trend-level association with the frontal horn on the right (P corrected = 0.073; Fig. 4 ; Table 2 ). After controlling for hippocampal atrophy, the association between ADL decline and right frontal horn enlargement also became significant (P corrected = 0.044). After controlling for baseline frontal horn or total ventricular volume, the association with the right body/ occipital horn trend-level and the association with the right frontal horn were nonsignificant ( Table 2 , maps not shown).
All the above analyses were reran with % volumetric increase as the dependent variable and all cognitive measures as predictor variables first unadjusted and then also while adjusting for total ventricular, frontal horn volume at baseline or hippocampal atrophy overtime. The results are provided in Supplementary Table 1, http://links.lww.com/ WAD/A33. Overall volumetric regression models proved less powerful for detecting associations between the selected cognitive measures and ventricular change over time relative to ventricular radial distance.
DISCUSSION
The most significant ventricular differences between MCIc and MCInc with minimal hippocampal involvement at baseline and at follow-up were localized to the frontal horns. These differences suggest greater underlying frontal lobe atrophy in MCIc versus MCInc. The frontal lobes have been long recognized as the seat of executive control. Executive function-one's ability to operate independently, solve problems, monitor, and alter behavior to achieve a preselected task-is essential for independent living. Executive dysfunction is predictive of progression from MCI to AD 23 and manifests with impairments in ADL. Thus, it is not surprising that of all clinical and cognitive measures, decline in ADL and executive function measured by the Maze Task showed the strongest associations with progressive enlargement of the frontal regions of the lateral ventricles. These data and the observed posterior predominant associations of the visuospatial measure and the left temporal horn association of the verbal memory measure suggest a functionally relevant regionally specific pattern of lateral ventricular changes in AD.
Our data extend previous work of our and other groups. Although several groups have reported greater lateral ventricular expansion in MCIc relative to MCInc over time, 1, 6, 24 these groups have not provided evidence for regionally specific clinically relevant pattern of involvement as we have here. In addition, all studies of ventricular changes in MCI to date have focused on the typical MCI subjects, many of whom show pronounced hippocampal atrophy. Here, our goal was to investigate for potentially useful predictor of clinical progression among MCI subjects who upon visual inspection do not show MTA greater than what one might expect to result from normal aging alone. Our findings suggest that in the absence of pronounced hippocampal involvement, enlargement of the frontal horns of the lateral ventricle might become a useful predictive biomarker for future conversion from MCI to AD.
Strengths of our study include the selection of a large well-defined prospectively collected and exceptionally wellcharacterized longitudinal MCI sample and the use of sensitive state-of-the-art ventricular analytic techniques. Clinical trials aim to enroll a "clean" subject pool with a specific, tightly defined, clinical presentation, minimal comorbidities, and carefully mandated allowable medication regimens. One limitation imposed by the clinical trial design stems from the fact that enrolled participants are frequently healthier than the general population; patients with multiple medical problems are excluded. As such, an epidemiologic data set might be better poised to provide truly unbiased evidence about MCI and AD cognitive and functional decline and disease progression as manifested in structural brain changes. Nevertheless, developing biomarker tools in clinical trial populations is tremendously valuable, as a biomarker validated in epidemiological studies may easily underperform in clinical trials due to the stringent refinement of the trial participants as mandated by the strict inclusion and exclusion criteria. 13, 25 Another limitation of our study is the lack of definitive diagnosis. The latter requires postmortem histopathologic examination, which is not available on our participants. The inclusion of MMSE data in our analyses was not guided by its sensitivity and specificity for the MCI population but rather by the fact that this is one of the most commonly used global cognitive screens in the dementia literature and that it has been most exhaustively researched in the past. Finally, the imaging data analyzed here come from a wellknown clinical trial. As such our research participants were randomized to donepezil, vitamin E, or placebo. Donepezil is an FDA-approved therapy for AD and as such it could potentially have an effect on hippocampal atrophy. Although no treatment effect on any of the imaging measures including hippocampal atrophy was seen in the original analyses published by Jack et al in 2008, 14 a concern that donepezil or vitamin E could have a differential effect on ventricular enlargement and can thus affect our analyses remained. However, as demonstrated in Table 1 , the proportion of MCIc and MCInc subjects in each treatment arm were nearly identical (ie, 25% MCIc and 26% MCInc were assigned to donepezil, 32% MCIc and 31% MCInc were assigned to vitamin E, and 43% MCIc and 43% MCInc were assigned to placebo, ANOVA P = 0.98). Such negligible and statistically insignificant differences are highly unlikely to have influenced our analyses. 
